Significant clinical and commercial opportunity of NTCD-M3 confirmed by positive data from US research study and new market research
- US Department of Veterans Affairs study confirms the potential of NTCD-M3 as a novel treatment to prevent the recurrence of CDI that can be used alongside all standard-of-care antibiotic treatments
- US and European market research underpins clinical support and market opportunity
Brighton, United Kingdom, 24 January 2022 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces the successful outcome of the Cooperative R&D agreement with the US Department of Veterans Affairs with NTCD-M3, a novel microbiome therapeutic being developed to reduce the recurrence of Clostridioides difficile infections (CDI) in the gut. The research results confirmed NTCD-M3’s ability to colonise the gut after antibiotic administration, which strengthens the market opportunity as it supports its use following commonly used antibiotic treatments. The Company also announces findings from North American and European market research which reinforce the clinical support and market potential of NTCD-M3.